|Bid||1.76 x 21500|
|Ask||2.04 x 900|
|Day's Range||1.90 - 2.24|
|52 Week Range||1.68 - 5.10|
|Beta (3Y Monthly)||0.82|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In case you missed it, here are some of Benzinga's top stories from Thursday, March 15th, 2018. Energy Stocks And ETFs Struggle For energy investors, the weakness in energy stocks and ETFs that characterized ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to VBI Vaccines, Inc. Here are 5 ETFs with the largest exposure to VBIV-US. Comparing the performance and risk of VBI Vaccines, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis VBI Vaccines, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of VBI Vaccines, Inc. – Pieris Pharmaceuticals, Inc. and PDL BioPharma, Inc. (PIRS-US and PDLI-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 0.19 ... Read more (Read more...)
VBI Vaccines, Inc. - Ordinary Shares (NASDAQ: VBIV ) will release results on three clinical trials in the first half of 2018, presenting certain investment opportunities of an uncertain nature. Some on ...
NASDAQ:VBIV VBI Vaccines, Inc. (NASDAQ:VBIV) is a Cambridge, Massachusetts-based biopharmaceutical company developing a portfolio of vaccines including solutions for hepatitis B, cytomegalovirus (CMV) ...